Europe Dengue Treatment Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2021 –2028 |
 Marktgröße (Basisjahr) | USD 14.94 Million |
 Marktgröße (Prognosejahr) | USD 73.75 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
Europe Dengue Treatment Market, By Strains (DENV-1, DENV-2, DENV-3, DENV-4 and Others), Transmission (Mosquito-To-Human Transmission, Mother-To-Child Transmission and Others), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania and Rest of Europe) Industry Trends and Forecast to 2028
Market Analysis and Insights: Europe Dengue Treatment Market
Dengue treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 22.5% in the forecast period of 2021 to 2028 and is expected to reach USD 73.75 million by 2028 from USD 14.94 million in 2020. Strategic initiatives by market players and advent of mass vaccination programmes for dengue treatment are likely to be the major drivers which propelled the demand of the market in the forecast period.
Dengue fever is a mosquito- borne viral infection. Female mosquitoes transmit the dengue virus primarily from the species Aedes aegypti and to a lesser degree, from Ae. albopictus. Chikungunya, yellow fever and Zika viruses are the disease caused by these vector mosquitoes. Dengue is prevalent in the tropics, with local risk variability caused by precipitation, temperature, relative humidity and unplanned rapid urbanizationThe diagnosis of dengue fever is difficult, since its signs and symptoms are similar to those of chikungunya, Zika virus, malaria and typhoid fever. Dengue is a mosquito-borne tropical disease caused by the dengue virus (DENV-1, DENV-2, DENV-3, DENV-4). Symptoms typically begin three to fourteen days after infection.
The treatment of dengue is totally based on treating the symptoms such as for high fever, acetaminophen is generally prescribed to control fever and relives pain. Aspirin and ibuprofen should be avoided for treating dengue fever. In case of severe dengue supportive care is given with the proper monitoring of the symptoms such as belly pain, internal bleeding and shock.
Acetaminophen, chloramphenicol, ciprofloxacin, ceftriaxone, ranitidine, pantoprazole are prescribed in dengue fever, with supportive care and available vaccines in the market. The increasing prevalence of dengue, advent of vaccination programs, growth of medical insurance in emerging countries and increasing R&D funding expected to drive the dengue treatment market growth. Moreover, strategic initiative by market player and technological development to detect dengue bolsters the dengue treatment market growth.
The dengue treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Dengue Treatment Market Scope and Market Size
Dengue treatment market is segmented on the basis of strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of strain, the dengue treatment market is segmented into DENV-1, DENV-2, DENV-3, DENV-4, others. In 2021, DENV-2 segment is dominating the market as this strain is high in prevalence globally which result in higher infection cases of dengue fever. Although dengue can be csued by other strains too but the most dominant high clinical complication is seen in DENV-2.
- On the basis of transmission, the dengue treatment market is segmented into mosquito-to-human transmission and mother-to-child transmission. In 2021, mosquito-to-human is dominating in the market as the mosquitoes are the primary vector for the transmission of dengue for the different strains of the virus. When a mosquito bites an infected person it gets infected too and gets the virus in blood, and when a he again bite some other person the virus get transmitted to that person. This is the reason that mosquito-to-human transmission is dominating the market.
- On the basis of type, the dengue treatment market is segmented into medication, supportive care, vaccination and others. In 2021, medication segment are dominating in the Europe Dengue Treatment Market as variety of drugs used for treating dengue are being used for the management of dengue fever from the very long time.
- On the basis of severity, the dengue treatment market is segmented into uncomplicated and severe. In 2021, uncomplicated segment is dominating in the Europe Dengue Treatment Market as the conversion rate of uncomplicated dengue to severe dengue is less than 5% which is the most important reason that the uncomplicated segment is dominating the Europe Dengue Treatment Market.
- On the basis of route of administration, the dengue treatment market is segmented into oral and parenteral. Oral is sub-segmented into tablets, pills and others. Parenteral is sub-segmented into intravenous, subcutaneous and others. In 2021, oral segment is dominating in the Europe Dengue Treatment Market as most of the drug that are taken to treat the symptoms of dengue are taken oral for pain management and fever management.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and OTC. In 2021, prescription is dominating in the Europe Dengue Treatment Market as the medication and the supportive care is prescribed by the doctor after the confirmation the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2021, home healthcare is dominating the Europe Dengue Treatment Market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the Europe Dengue Treatment Market as after proper diagnosis of dengue most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.
Dengue Treatment Market Country Level Analysis
The dengue treatment market is analysed and market size information is provided by country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel.
The countries covered in the dengue treatment market report are Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania and Rest of Europe.
Europe is expected to grow with the CAGR in the forecasted period due to growing R&D activities in pharma and biotech sector. Germany is expected to dominate in the Europe market. Germany is one of the leading countries in automation with increasing number of upgradation of the software driven compound management.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Necessity of Dengue Treatment in Urban Areas and the Strategic Initiatives by Market Players are creating new Opportunities in the Dengue Treatment Market
Dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Dengue Treatment Market Share Analysis
Dengue treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to dengue treatment market.
The major companies providing dengue treatment are Takeda Pharmaceutical Company Limited, Sanofi, EMERGEX VACCINES, ABIVAX, GlaxoSmithKline plc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Baxter, among others.
The strategic initiatives by market players with capital investment for dengue research are bridging the gap between dengue and its treatment.
- In 2016, Sun Pharmaceutical Industries Ltd. and International Centre for Genetic Engineering and Biotechnology (ICGEB) announced collaboration for developing novel dengue vaccine for India and global market.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the dengue treatment market which also provides the benefit for organisation to improve their offering for treatment products.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE DENGUE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STRAINS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 PIPELINE ANALYSIS
6 EUROPE DENGUE TREATMENT MARKET: REGULATIONS
6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.
7.1 SYNTHETIC DRUGS
7.2 BIOMARKER
7.3 DIRECT ACTING ANTIVIRAL DRUGS
8 EPIDEMIOLOGY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING INCIDENCE IN DENGUE CASES
9.1.2 ADVENT OF VACCINATION PROGRAMS
9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING
9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE
9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
9.2 RESTRAINTS
9.2.1 HIGH COST OF TREATMENT
9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE
9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE
9.3 OPPORTUNITIES
9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION
9.3.4 INCREASE IN EUROPE TRAVEL AND RELATION WITH DENGUE
9.4 CHALLENGES
9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD
9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE
9.4.3 ALTERNATIVES FOR DENGUE TREATMENT
10 IMPACT OF COVID-19 ON EUROPE DENGUE TREATMENT MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISION BY MANUFACTURERS
10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
10.6 CONCLUSION
11 EUROPE DENGUE TREATMENT MARKET, BY STRAINS
11.1 OVERVIEW
11.2 DENV-3
11.3 DENV-2
11.4 DENV-1
11.5 DENV-4
11.6 OTHERS
12 EUROPE DENGUE TREATMENT MARKET, BY TRANSMISSION
12.1 OVERVIEW
12.2 MOSQUITO-TO-HUMAN TRANSMISSION
12.3 MOTHER-TO-CHILD- TRANSMISSION
12.4 OTHERS
13 EUROPE DENGUE TREATMENT MARKET, BY TYPE
13.1 OVERVIEW
13.2 MEDICATION
13.2.1 ACETAMINOPHEN
13.2.2 ANTIBIOTICS
13.2.2.1 Ciprofloxacin
13.2.2.2 Chloramphenicol
13.2.2.3 Ceftriaxone
13.2.2.4 Ofloxacin
13.2.2.5 Others
13.2.3 IMMUNOGLOBULINS
13.2.4 CORTICOSTEROIDS
13.2.5 ANTI-VIRALS
13.2.6 OTHERS
13.3 SUPPORTIVE CARE
13.4 VACCINATION
13.4.1 DENGVAXIA (CYD-TDV)
13.4.2 DENVAX (TAK-003)
13.4.3 TETRAVAX-DV
13.4.4 TDEN PIV
13.5 OTHERS
14 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY
14.1 OVERVIEW
14.2 UNCOMPLICATED
14.3 SEVERE
15 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
16 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 PRESCRIPTION
16.3 OVER THE COUNTER (OTC)
17 EUROPE DENGUE TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOME HEALTHCARE
17.3 HOSPITALS
17.4 SPECIALTY CLINICS
17.5 OTHERS
18 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 RETAIL PHARMACIES
18.3 HOSPITAL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 EUROPE DENGUE TREATMENT MARKET, BY GEOGRAPHY
19.1 EUROPE
19.1.1 GERMANY
19.1.2 U.K.
19.1.3 FRANCE
19.1.4 ITALY
19.1.5 SPAIN
19.1.6 BELGIUM
19.1.7 AUSTRIA
19.1.8 POLAND
19.1.9 NORWAY
19.1.10 IRELAND
19.1.11 HUNGARY
19.1.12 LITHUANIA
19.1.13 TURKEY
19.1.14 SWITZERLAND
19.1.15 NETHERLANDS
19.1.16 RUSSIA
19.1.17 REST OF EUROPE
20 EUROPE DENGUE TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: EUROPE
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 VIATRIS INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 COMPANY SHARE ANALYSIS
22.1.3 PRODUCT PORTFOLIO
22.1.4 RECENT DEVELOPMENT
22.2 PFIZER INC.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENT
22.4 PERRIGO COMPANY PLC
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 GLAXOSMITHKLINE PLC
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 COMPANY SHARE ANALYSIS
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENT
22.6 DR. REDDY’S LABORATORIES LTD.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENT
22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENTS
22.9 ABIVAX
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 AUROBINDO PHARMA
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 BAXTER
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENT
22.12 EMERGEX VACCINES
22.12.1 COMPANY SNAPSHOT
22.12.2 PRODUCT PORTFOLIO
22.12.3 RECENT DEVELOPMENTS
22.13 HIKMA PHARMACEUTICALS PLC
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENT
22.14 SANOFI
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 EUROPE DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 EUROPE DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 EUROPE DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 EUROPE ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 EUROPE SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 EUROPE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 EUROPE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 EUROPE UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 EUROPE SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 EUROPE PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 EUROPE OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 EUROPE HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 EUROPE HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 EUROPE SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 EUROPE DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 EUROPE HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 EUROPE ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 EUROPE HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 EUROPE DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 EUROPE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 EUROPE ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 GERMANY DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 GERMANY MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 GERMANY ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 GERMANY OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 GERMANY VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 U.K. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 U.K. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.K. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.K. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 U.K. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 U.K. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 U.K. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 FRANCE DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 FRANCE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 FRANCE ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 FRANCE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 FRANCE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 101 ITALY DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 102 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 ITALY MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 ITALY ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 ITALY OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 ITALY VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 108 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 ITALY ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 111 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 112 ITALY DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 113 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 114 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 115 SPAIN DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 116 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 SPAIN MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 SPAIN ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 SPAIN OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 SPAIN VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 122 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 125 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 126 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 127 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 128 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 129 BELGIUM DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 130 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 BELGIUM MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 BELGIUM ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 BELGIUM OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 BELGIUM VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 136 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 139 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 140 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 141 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 142 AUSTRIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 143 AUSTRIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 144 AUSTRIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 AUSTRIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 150 AUSTRIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 AUSTRIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 AUSTRIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 153 AUSTRIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 154 AUSTRIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 155 AUSTRIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 156 POLAND DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 157 POLAND DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 158 POLAND DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 POLAND MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 POLAND ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 161 POLAND OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 162 POLAND VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 163 POLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 164 POLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 POLAND ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 POLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 POLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 168 POLAND DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 POLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 NORWAY DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 171 NORWAY DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 172 NORWAY DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 NORWAY MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 NORWAY ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 NORWAY OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 NORWAY VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 NORWAY DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 178 NORWAY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 179 NORWAY ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 NORWAY PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 NORWAY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 182 NORWAY DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 183 NORWAY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 IRELAND DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 185 IRELAND DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 186 IRELAND DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 187 IRELAND MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 IRELAND ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 IRELAND OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 IRELAND VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 IRELAND DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 192 IRELAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 193 IRELAND ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 194 IRELAND PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 195 IRELAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 196 IRELAND DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 197 IRELAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 198 HUNGARY DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 199 HUNGARY DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 200 HUNGARY DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 HUNGARY MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 HUNGARY ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 HUNGARY OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 HUNGARY VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 HUNGARY DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 206 HUNGARY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 HUNGARY ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 HUNGARY PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 209 HUNGARY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 210 HUNGARY DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 211 HUNGARY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 212 LITHUANIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 213 LITHUANIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 214 LITHUANIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 215 LITHUANIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 216 LITHUANIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 217 LITHUANIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 LITHUANIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 LITHUANIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 220 LITHUANIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 221 LITHUANIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 222 LITHUANIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 223 LITHUANIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 224 LITHUANIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 225 LITHUANIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 226 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 227 TURKEY DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 228 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 229 TURKEY MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 230 TURKEY ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 231 TURKEY OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 232 TURKEY VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 233 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 234 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 235 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 236 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 237 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 238 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 239 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 240 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 241 SWITZERLAND DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 242 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 SWITZERLAND MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 SWITZERLAND ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 SWITZERLAND OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 SWITZERLAND VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 248 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 249 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 250 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 251 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 252 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 253 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 254 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 255 NETHERLANDS DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 256 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 257 NETHERLANDS MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 NETHERLANDS ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 NETHERLANDS OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 NETHERLANDS VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 261 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 262 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 263 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 265 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 266 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 267 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 268 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 269 RUSSIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 270 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 RUSSIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 RUSSIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 RUSSIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 274 RUSSIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 275 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 276 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 278 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 279 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 280 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 281 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 282 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 EUROPE DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE DENGUE TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 EUROPE DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE EUROPE DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF EUROPE DENGUE TREATMENT MARKET
FIGURE 15 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 EUROPE DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 EUROPE DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 EUROPE DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 EUROPE DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 EUROPE DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 EUROPE DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 EUROPE DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 EUROPE DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 EUROPE DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 EUROPE DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 EUROPE DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 EUROPE DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 EUROPE DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 EUROPE DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 EUROPE DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 EUROPE DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 EUROPE DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
